Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant ChemotherapyIdentification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

ABSTRACT: Neoadjuvant chemotherapy (NAC) has been of recent interest as an alternative to upfront surgery followed by adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). However, a subset of patients does not respond to NAC and may have been better managed by upfront surgery. Hence, there is an unmet need for accurate biomarkers for predicting NAC response in PDAC. This project aimed to identify upregulated proteins in tumor tissue from poor- and good-NAC responders.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Pancreatic Ductal Cell, Pancreas

DISEASE(S): Pancreatic Ductal Carcinoma

SUBMITTER: Sumit Sahni  

LAB HEAD: Anubhav Mittal

PROVIDER: PXD017051 | Pride | 2020-04-16

REPOSITORIES: Pride